Vaccinex Company Description
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders.
The company’s lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.
It is developing Pepinemab, which is in phase 2 clinical for the treatment of Alzheimer’s disease and has completed phase 2 study for the treatment of Huntington’s disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer; Pepinemab in combination with Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 clinical trial with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab and/or Ipilimumab which is in phase 2 clinical trial for melanoma; Pepinemab in combination with Trastuzumab and dendritic cell vaccines in phase 2 clinical trial for breast cancer.
The company has also developed ActivMAb, a human antibody discovery platform based on a novel method for expressing and presenting complex multipass membrane proteins, as well as full-length human monoclonal antibodies on the surface of mammalian pox viruses.
In addition, it develops CHS-114 and anti-CCR8 antibody; and VX5, which is in preclinical development to treat related to autoimmune disorders.It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; Emory University; Huntington Study Group; Catalent Pharma Solutions, LLC; and Surface Oncology, Inc. The company was incorporated in 2001 and is headquartered in Rochester, New York.
| Country | United States |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Maurice Zauderer |
Contact Details
Address: 1895 Mount Hope Avenue Rochester, Delaware 14620 United States | |
| Phone | 585 271 2700 |
| Website | vaccinex.com |
Stock Details
| Ticker Symbol | VCNX |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US9186401033 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Maurice Zauderer Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Elizabeth E. Evans Ph.D. | Chief Operating Officer and Senior Vice President of Discovery and Translational Medicine |
| Dr. Ernest S. Smith Ph.D. | Senior Vice President of Research and Chief Scientific Officer |
| Jill Sanchez CPA | Chief Financial Officer |